Navigation Links
3SBio Inc. Announces Second Quarter 2008 Results
Date:8/12/2008

. These statements are based upon 3SBio management's current expectations, and actual results could differ materially. Among the factors that could cause 3SBio's actual results to differ from what the company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; the completion of 3SBio's ongoing clinical trials as planned; receipt and timing of regulatory approvals for 3SBio's new products and uses; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors that may affect the 3SBio's financial results, please refer to the company's filings with the Securities and Exchange Commission at http://www.sec.gov . 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

For more information, please contact:

Investor Contact:

Kevin Teo, CFO

3SBio Inc.

No.3 A1, Road 10, Shenyang Development Zone

Shenyang, China 110027

Tel: +86 (24) 2581-1820

Email: IR@3sbio.com

Web: http://www.3SBio.com

Investor Relations (US):

Mahmoud Siddig, Director

Taylor Rafferty

205 Lexington Avenue 8th Floor

New York
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... (Nasdaq: VRUS ), a clinical stage pharmaceutical ... to treat viral infections, reported financial results and operational ... Financial Results Revenues were $1.9 million during the ... for the quarter ended March 31, 2008 and reflect ...
... Iceland, May 11 deCODE genetics,(Nasdaq: DCGN ) ... March 31, 2009. A conference call to discuss these ... webcast live tomorrow,Tuesday, May 12, at 8:00am Eastern Daylight ... Net loss for the quarter ended ...
... MOUNTAIN VIEW, Calif., May 11 VIVUS, Inc. (Nasdaq: ... and commercialization of novel therapeutic products, today reported its highlights and ... First Quarter 2009 Highlights: , ... European Patent for Qnexa - In January 2009, we announced ...
Cached Biology Technology:Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8deCODE genetics Announces First Quarter 2009 Financial Results 2deCODE genetics Announces First Quarter 2009 Financial Results 3deCODE genetics Announces First Quarter 2009 Financial Results 4deCODE genetics Announces First Quarter 2009 Financial Results 5deCODE genetics Announces First Quarter 2009 Financial Results 6deCODE genetics Announces First Quarter 2009 Financial Results 7deCODE genetics Announces First Quarter 2009 Financial Results 8VIVUS Reports First Quarter 2009 Financial Results and Highlights 2VIVUS Reports First Quarter 2009 Financial Results and Highlights 3VIVUS Reports First Quarter 2009 Financial Results and Highlights 4VIVUS Reports First Quarter 2009 Financial Results and Highlights 5VIVUS Reports First Quarter 2009 Financial Results and Highlights 6VIVUS Reports First Quarter 2009 Financial Results and Highlights 7
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... A molecule that helps the body's motor nerve cells ... a major role in inhibiting spinal-cord neurons from regenerating ... found. In cultured cells, the researchers found that a ... stabilizes long nerve fibers in adult vertebrates ?chemically blocks ...
... researchers first to report function of tunneling nanotubules , ... an extensive network of tiny tunnels that, like a ... signals to distant cells. This surprising discovery, being reported ... in the September issue of the journal Immunity, may ...
... seeking ways to eliminate pollution from waterways with microbes ... freshwater ponds can generate electricity. They present their findings ... Society for Microbiology. , "The bacteria are capable of ... to operate small electronic devices. As long as the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3'Underground' tunnels discovered as means for communication between immune system cells 2'Underground' tunnels discovered as means for communication between immune system cells 3'Underground' tunnels discovered as means for communication between immune system cells 4Pollution-eating bacteria produce electricity 2
... siRNA library screening, optimal siRNA ... and verified for each cell ... siRNA Transfection Optimization Kit, which ... transfection conditions in 96 well ...
... Series of positioning slides offers multiple ... leadscrew, micrometer, and manual. With this ... cost-effective multi-axis systems. These slides also ... resolutions down to 10 nanometers, integrated ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: